RT Journal Article
SR Electronic
T1 HEART rate variability biofeedback breathing programme for LOng Covid dysautonomia (HEARTLOC): results of a feasibility study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.09.23295208
DO 10.1101/2023.09.09.23295208
A1 Corrado, J
A1 Iftekhar, N
A1 Halpin, SJ
A1 Li, M
A1 Tarrant, R
A1 Grimaldi, J
A1 Simms, AD
A1 O’Connor, RJ
A1 Casson, AJ
A1 Sivan, M
YR 2023
UL http://medrxiv.org/content/early/2023/09/12/2023.09.09.23295208.abstract
AB Introduction Post-covid-19 syndrome, or Long covid (LC) refers to symptoms persisting 12 weeks after Covid-19 infection. LC comprises a wide range of dysautonomia symptoms, including fatigue, breathlessness, palpitations, dizziness, pain and brain fog. This study tested the feasibility and estimated the efficacy, of a Heart Rate Variability Biofeedback (HRV-B) technique via a standardised slow diaphragmatic breathing programme in individuals with LC.Methods and Analysis LC patients underwent a 4-week HRV-B intervention for 10 minutes twice daily for a total of 4 weeks using the Polar H10 ECG (Electrocardiogram) chest strap and Elite HRV phone application. Outcome measures C19-YRSm (Yorkshire Rehabilitation Scale modified), EQ5D-5L (EuroQol 5 Dimensions), Composite Autonomic Symptom Score (COMPASS-31), WHO Disability Assessment Schedule (WHODAS), and Root Mean Square of Successive Differences between heartbeats (RMSSD) using a Fitbit device were completed before and after the intervention. The study was pre-registered at clinicaltrials.gov NCT05228665.Results 13 participants (54% female, 46% male) completed the study with high levels of data completeness and adherence. There was a statistically significant improvement in C19YRS-m (p=0.001), EQ5D Global Health Score (p=0.009), COMPASS-31 (p=0.007), RMSSD (p=0.047) and EHODAS (p=0.02). Qualitative feedback suggested participants were able to use it independently, were satisfied with the intervention, and reported beneficial effects from the intervention.Conclusion This is the first study in the literature to report that HRV-B is a feasible intervention for LC and seems to be potentially improving symptoms of LC and dysautonomia.Strengths and limitations of the studyTo our knowledge, this is the first study of HRV-B in long covid and dysautonomia and has shown the feasibility of a novel technology-based intervention in a home setting.There was a statistically significant improvement in LC symptoms, functional ability, quality of life and dysautonomia scores.The study provides an estimation of efficacy which will determine the sample size for a larger controlled trial in LC and dysautonomia.The main limitation of this study is the small sample size and uncontrolled design which might not give us an accurate estimate of efficacy.The sample was predominantly Caucasian participants, 54% of whom were female.The take-up for HRV-B in those with a lack of experience in using digital technology and those from less privileged backgrounds is unknown.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study was pre-registered at clinicaltrials.gov NCT05228665Clinical Protocols https://pubmed.ncbi.nlm.nih.gov/36410797/ Funding StatementThis research was supported by IAA EPSRC grant [Ref 112538] with the University of Leeds as the sponsor organisation and the Leeds Community Healthcare NHS Trust Covid Rehabilitation service as the research site organisation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical approval from Health Research Authority (HRA) Leicester South Research Ethics Committee (21/EM/0271).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors